Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101 reduced hematoma volume and slowed perihematomal edema growthTrend to functional recovery with BIOX-101 more favorable than in SoC groupConsistent anti-inflammatory biomarker responses aligned with positive clinical efficacy signalsNo deaths after a mean follow-up of 8 monthsLaunching Series B financing to fund potentially registrational Phase 2b trial Gosselies, Belgium, 11 September 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces encouraging second interim results from the BIRCH Phase 2a clinical trial of its lead asset, BIOX-101, to treat intracerebral hemorrhage (ICH). The results confirm and expand upon the positive findings of the first set of interim results, announced in April. The new data show that all patients treated with BIOX-101 experienced a reduction in hematoma. This finding was further supported by biomarker measurements, all of which trended in support of the clinical observations. The Data Monitoring Committee in its recommendation unanimously endorsed proceeding to a Phase 2b or Phase 3 efficacy trial.
Read full article


